Benchmark reissued their speculative buy rating on shares of Genelux (NASDAQ:GNLX - Free Report) in a research note published on Wednesday, Benzinga reports. They currently have a $30.00 price target on the stock.
Separately, HC Wainwright lowered their target price on Genelux from $35.00 to $32.00 and set a buy rating for the company in a report on Tuesday.
View Our Latest Stock Analysis on GNLX
Genelux Price Performance
GNLX traded down $0.39 during trading hours on Wednesday, reaching $4.86. 131,135 shares of the company's stock traded hands, compared to its average volume of 118,746. The firm has a 50-day moving average price of $7.50 and a 200 day moving average price of $13.19. Genelux has a 52-week low of $4.86 and a 52-week high of $40.98.
Institutional Investors Weigh In On Genelux
Several hedge funds have recently made changes to their positions in GNLX. Tower Research Capital LLC TRC bought a new position in shares of Genelux in the 1st quarter worth $32,000. Citigroup Inc. acquired a new position in Genelux during the 1st quarter valued at about $84,000. Charles Schwab Investment Management Inc. acquired a new position in Genelux during the 1st quarter valued at about $421,000. BlackRock Inc. acquired a new position in Genelux during the 1st quarter valued at about $402,000. Finally, Geode Capital Management LLC acquired a new position in Genelux during the 1st quarter valued at about $1,046,000. 37.33% of the stock is currently owned by hedge funds and other institutional investors.
About Genelux
(
Get Free Report)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Further Reading
Before you consider Genelux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genelux wasn't on the list.
While Genelux currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
